financetom
Business
financetom
/
Business
/
JPMorgan Quarterly Earnings Estimate Cut by Morgan Stanley on Disappointing Investment Banking Outlook
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
JPMorgan Quarterly Earnings Estimate Cut by Morgan Stanley on Disappointing Investment Banking Outlook
May 26, 2025 11:03 AM

12:07 PM EDT, 05/20/2025 (MT Newswires) -- JPMorgan Chase ( JPM ) is now expected to report lower second-quarter earnings than previously estimated by Morgan Stanley, after the banking giant issued a downbeat outlook for investment banking fees and the markets division.

JPMorgan ( JPM ) forecasts investment banking fees to be down by a mid-teens percentage figure on an annual basis in the second quarter, Troy Rohrbaugh, co-chief executive of commercial and investment bank, said at its investor day held Monday. The consensus was for an 8% decline, Morgan Stanley said in a client note emailed Tuesday.

"We're in a challenging environment with potential downward pressures on investment banking wallet, acute competition and (an) increasing war for talent," Rohrbaugh said, according to a FactSet transcript. "But we will continue to expand our client franchise through our targeted growth initiatives."

The markets division is seen rising by a mid- to high-single digit in the ongoing quarter, he said. Morgan Stanley put the consensus view at 10% growth.

Morgan Stanley cut JPMorgan's ( JPM ) earnings forecast to $4.72 per share for the current quarter from $4.77, citing lower investment banking fees. The average analyst estimate on FactSet is for GAAP EPS of $4.43 and non-GAAP EPS of $4.46.

The lender continues to expect net interest income, excluding markets, at about $90 billion for 2025, Chief Financial Officer Jeremy Barnum said at the investor day. Barnum acknowledged that the outlook is "probably slightly better" than what was provided when the bank reported its first-quarter results in April.

Morgan Stanley sees "plenty" of growth runway ahead for JPMorgan ( JPM ). The brokerage raised its forecast for JPMorgan's ( JPM ) 2026 EPS to $19.63 from $19.57 amid "slightly higher" consumer and community banking deposit and commercial and investment bank loan growth rates in 2025 and 2026.

Morgan Stanley increased its price target on JPMorgan's ( JPM ) stock to $236 from $235, with an equal-weight rating.

Price: 266.15, Change: +1.26, Percent Change: +0.48

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Copyright 2023-2026 - www.financetom.com All Rights Reserved